The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC).
 
Ferdinandos Skoulidis
Consulting or Advisory Role - Aimmune (I); Amgen; AstraZeneca; Beigene; BergenBio; Bridgebio; Bristol-Myers Squibb; Guardant Health; Hookipa Pharma; Merck; Novartis; Novocure; Regeneron; Revolution Medicines; Roche; Roche (I); Tango Therapeutics
Research Funding - Amgen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Revolution Medicines (Inst)
Travel, Accommodations, Expenses - AACR; Amgen; AstraZeneca; Bristol-Myers Squibb; Curio/Vaniam Group; DAVA Oncology; IASLC; Ideology Health; MI&T; MJH Life Sciences; PER; Revolution Medicines; Tango Therapeutics
Other Relationship - American Association for Cancer Research; Amgen; AstraZeneca; CURIO LLC; DAVA Oncology; ESMO; Genentech/Roche; IASLC; Ideology Health; Intellisphere; Japanese Lung Cancer Society; McGill Universite de Montreal; Medscape; Merck; MI&T; MJH Life Sciences; Novartis; PER; Pfizer; Promocao Events LTDS; Revolution Medicines; RV Mais; Tango Therapeutics
 
Benjamin Solomon
Honoraria - Amgen (Inst); AstraZeneca; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Lilly; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech (Inst); Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Nikolaj Frost
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Berlin-Chemie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Sanofi/Aventis; Takeda
Research Funding - Roche Pharma AG
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Lilly; Roche Pharma AG; Takeda
(OPTIONAL) Uncompensated Relationships - Deutsche Forschungsgemeinschaft; Deutsche Krebsgesellschaft, Arbeitsgemeinschaft Internistische Onkologie; German Society for Pneumology and Respiratory Medicine
 
Rebecca Heist
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Biohaven Pharmaceuticals; Claim Therapeutics; Daichii Sankyo; Daichii Sankyo; Genentech/Roche; Gilead Sciences; Lilly; Merck; Novartis; Regeneron; Sanofi
Research Funding - Abbvie (Inst); Agios (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Modex (Inst); Mythic Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Caicun Zhou
Leadership - IASLC BOD
Honoraria - Alice; Amoy Diagnostics; Anheart Therapeutics; Luye Pharma; Merck Sharpe and Dohme; MSD; QiLu Pharmaceutical; Sanofi; TopAlliance BioSciences Inc
Consulting or Advisory Role - Innovent Biologics; QiLu Pharmaceutical
 
Martina Zarak Crnkovic
Employment - Roche
 
Vladan Antic
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Hen Prizant
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
 
Mariah Clarisse Mayo
No Relationships to Disclose
 
Christoph Meyenberg
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Sophie Keufer-Le Gall
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Sanjay Popat
Consulting or Advisory Role - Amgen; Anheart Therapeutics; Arcus Biosciences; ArriVent Biopharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Ellipses Pharma; Erasca, Inc; Gilead Sciences; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Pierre Fabre; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)